Trial Profile
A Phase I Study of NeuroVax(TM), a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs IR 902 (Primary) ; Incomplete Freund's adjuvant
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Immune Response BioPharma
- 09 Mar 2020 Planned End Date changed from 1 Nov 2019 to 9 Nov 2024.
- 09 Mar 2020 Planned primary completion date changed from 1 Nov 2019 to 9 Nov 2024.
- 09 Mar 2020 Planned initiation date changed from 1 Nov 2017 to 31 Dec 2020.